The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...

Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

Focus on including foods high in calories, protein, and nutrients into your loved one’s diet when they are experiencing ...

With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...